|
||||||||||||||||||||||||||
| SEC Info℠ | | | Home | | | Search | | | My Interests | | | Help | | | Sign In | | | Please Sign In | |||||||
|
||||||||||||||||||||||||||
As Of Filer Filing For·On·As Docs:Size Issuer Filing Agent 4/15/21 Cell Source, Inc. 10-K 12/31/20 71:6.4M Pubco Reporting … Inc/FA |
Document/Exhibit Description Pages Size
1: 10-K Annual Report HTML 932K
2: EX-10.60 Material Contract HTML 110K
3: EX-10.61 Material Contract HTML 43K
4: EX-10.62 Material Contract HTML 56K
5: EX-10.63 Material Contract HTML 39K
6: EX-31.1 Certification -- §302 - SOA'02 HTML 24K
7: EX-32.1 Certification -- §906 - SOA'02 HTML 20K
14: R1 Cover HTML 57K
15: R2 Condensed Consolidated Balance Sheets HTML 89K
16: R3 Condensed Consolidated Balance Sheets HTML 47K
(Parenthetical)
17: R4 Condensed Consolidated Statements of Operations HTML 66K
18: R5 Consolidated Statements of Changes in HTML 72K
Stockholders' Equity
19: R6 Condensed Consolidated Statements of Cash Flows HTML 129K
20: R7 Business Organization, Nature of Operations and HTML 28K
Risks and Uncertainties
21: R8 Going Concern and Managements Plans HTML 24K
22: R9 Summary of Significant Accounting Policies HTML 55K
23: R10 Fair Value HTML 59K
24: R11 Accrued Expenses HTML 27K
25: R12 Accrued Compensation HTML 29K
26: R13 Advances Payable HTML 22K
27: R14 Notes Payable HTML 73K
28: R15 Income Taxes HTML 48K
29: R16 Stockholders Deficiency HTML 83K
30: R17 Commitments and Contingencies HTML 29K
31: R18 Related Party Transactions HTML 23K
32: R19 Subsequent Events HTML 31K
33: R20 Summary of Significant Accounting Policies HTML 99K
(Policies)
34: R21 Summary of Significant Accounting Policies HTML 25K
(Tables)
35: R22 Fair Value (Tables) HTML 58K
36: R23 Accrued Expenses (Tables) HTML 26K
37: R24 Accrued Compensation (Tables) HTML 29K
38: R25 Notes Payable (Tables) HTML 46K
39: R26 Income Taxes (Tables) HTML 51K
40: R27 Stockholders Deficiency (Tables) HTML 70K
41: R28 Going Concern and Management Plans (Detail HTML 31K
Narrative)
42: R29 Summary of Significant Accounting Policies HTML 27K
(Details)
43: R30 Summary of Significant Accounting Policies (Detail HTML 38K
Narrative)
44: R31 Fair value (Details) HTML 74K
45: R32 Fair Value (Details 1) HTML 37K
46: R33 Fair Value (Details Narrative) HTML 25K
47: R34 Accrued Expenses (Details) HTML 33K
48: R35 Accrued Compensation (Details) HTML 39K
49: R36 Advance Payable (Details Narrative) HTML 33K
50: R37 Notes Payable (Details) HTML 30K
51: R38 Notes Payable (Details 1) HTML 23K
52: R39 Notes Payable (Details 2) HTML 34K
53: R40 Notes Payable (Details 3) HTML 20K
54: R41 Notes Payable (Details Narrative) HTML 200K
55: R42 Income Taxes (Details) HTML 25K
56: R43 Income Taxes (Details 1) HTML 33K
57: R44 Income Taxes (Details 2) HTML 35K
58: R45 Income Taxes (Details 3) HTML 35K
59: R46 Income Taxes (Details Narrative) HTML 28K
60: R47 Stockholders Deficiency (Details) HTML 52K
61: R48 Stockholders Deficiency (Details 1) HTML 40K
62: R49 Stockholders Deficiency (Details 2) HTML 31K
63: R50 Stockholders Deficiency (Details 3) HTML 37K
64: R51 Stockholders Deficiency (Details 4) HTML 35K
65: R52 Stockholders Deficiency (Details Narrative) HTML 183K
66: R53 Commitments and Contingencies (Details Narrative) HTML 44K
67: R54 Related Party Transactions (Details Narrative) HTML 32K
68: R55 Subsequent Events (Details Narrative) HTML 105K
70: XML IDEA XML File -- Filing Summary XML 122K
69: EXCEL IDEA Workbook of Financial Reports XLSX 96K
8: EX-101.INS XBRL Instance -- clcs-20201231 XML 1.48M
11: EX-101.CAL XBRL Calculations -- clcs-20201231_cal XML 143K
13: EX-101.DEF XBRL Definitions -- clcs-20201231_def XML 552K
10: EX-101.LAB XBRL Labels -- clcs-20201231_lab XML 1.01M
12: EX-101.PRE XBRL Presentations -- clcs-20201231_pre XML 840K
9: EX-101.SCH XBRL Schema -- clcs-20201231 XSD 230K
71: ZIP XBRL Zipped Folder -- 0001640334-21-000923-xbrl Zip 148K
EXHIBIT 10.61
NEITHER THIS NOTE NOR THE SECURITIES INTO WHICH THIS NOTE IS CONVERTIBLE HAVE BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “ACT”), OR UNDER ANY STATE SECURITIES LAW AND NEITHER THIS NOTE NOR ANY INTEREST THEREIN NOR THE SECURITIES INTO WHICH THIS NOTE IS CONVERTIBLE MAY BE OFFERED, SOLD, TRANSFERRED, PLEDGED OR OTHERWISE DISPOSED OF EXCEPT PURSUANT TO AN EFFECTIVE REGISTRATION STATEMENT UNDER SUCH ACT AND SUCH LAWS OR AN EXEMPTION FROM REGISTRATION UNDER SUCH ACT AND SUCH LAWS WHICH, IN THE OPINION OF COUNSEL SATISFACTORY TO THE COMPANY, IS AVAILABLE.
CELL SOURCE, INC.
Second Amended and Restated
10.0% Convertible Note
| Maturity Date: | |
|
|
|
| Principal Amount: | $4,000,000 |
This Amended and Restated Convertible Note (the “Note”) is issued by Cell Source, Inc., a Nevada corporation (the “Company”), effective as of the 2nd day of March 2021 (the “Issuance Date”), to Darlene D. Soave (the “Lender”) pursuant to the exemptions from registration under the Securities Act of 1933, as amended, and amends and restates the 8% Convertible Note issued by the Company to the Lender effective as of October 28, 2019, as amended by the Amended and Restated 8% Convertible Note dated June 18,2020 and effective as of October 28, 2019, as amended by Amendment No. 1 thereto dated as of December 3, 2020. (collectively, the “Original Note”)
ARTICLE I
PAYMENTS OF PRINCIPAL AND INTEREST; EVENTS F DEFAULT
For value received, the Company promises to pay to Lender, or her registered assigns, the lesser of (a) Four Million Dollars ($4,000,000) or (b) the actual amount advanced to the Company by the Lender (the “Principal Amount”) pursuant to the terms, conditions and provisions of this Note. The Company shall pay interest to the Lender on the outstanding Principal Amount of this Note in accordance with Section 1.2 below and such interest shall accrue on each advance of funds from the Lender (each an “Advance”) from the date of such Advance. Schedule A hereto sets forth a list of all advances made prior to the date hereof. To the extent that any of such advances are represented by previously issued promissory notes, they will hereafter be governed by this Note.
The Company hereby expressly authorizes the Holder to record on Schedule A hereto the amount and date of each loan made hereunder after the date hereof and the date and amount of each payment of principal thereon. All such notations shall be presumptive as to the correctness thereof and the aggregate unpaid amount of loans set forth on such schedule shall be presumed to be the unpaid Principal Amount hereof, so long as the Holder has delivered to Company a copy of the schedule each time a new notation was made thereon.
| 1 |
Section 1.1
Section 1.2 Interest shall accrue daily from the date of each Advance at a rate equal to ten percent (10%) per annum and shall be payable, at the Company’s option, either in cash or as payment-in-kind in shares of the Company’s Common Stock, on the Maturity Date. If the Company elects to pay interest in shares of the Company’s Common Stock, the number of shares issuable shall be determined by diving the dollar value of the interest being paid by $0.75 (as such amount shall be equitably adjusted to give effect to stock splits, stock dividends and similar transactions).
Section 1.3 All payments of principal and interest shall be made to the Lender at the address set forth in Section 3.1or such other address as the Lender shall notify the Company in writing ten (10) days prior to the due date of any payment or upon any prepayment of this Note as provided herein.
Section 1.4 The occurrence of any of the following events of default ( each an “Event of Default”) shall, at the option of the Lender, make all sums of principal and interest then remaining unpaid hereon and all other amounts payable hereunder immediately due and payable, upon demand, without presentment:
(a) the Company fails to pay the Principal Amount and all accrued and unpaid interest on or before the Maturity Date.
(b) the Company breaches any other provision of this Note and such breach is not cured within twenty (20) days after written notice thereof to the Company.
(c) bankruptcy or insolvency proceedings or other proceedings or relief under any bankruptcy law or any other law, or the issuance of any notice in relation to such event, for the relief of debtors shall be instituted by the Company.
ARTICLE II
CONVERSION RIGHTS; CONVERSION PRICE
Section 2.1 Conversion. The Company may elect to convert this Note into a number of fully paid and non-assessable shares of the Company’s Series B Convertible Preferred Stock (the “Series B Stock”) at a conversion price (the “Conversion Price”) equal to $7.50 per share at any time after the creation of the Series B Stock and before the Maturity Date. If the Company elects to convert this Note into Series B Stock pursuant to this Section 2.1, the Company shall deliver a notice of such conversion to the Lender. Upon receipt of such notice, the Lender shall promptly deliver this Note to the Company for cancellation and the Company shall issue and deliver to Lender the applicable number of shares of Series B Stock.
Section 2.2 Warrant. For each $500,000 of Advances provided by Lender under this Note, the Company shall issue to Lender a warrant to purchase 400,000 shares of the Company’s Common Stock at an exercise price of $1.25 per share. Each warrant will have a five (5) year term. The Lender hereby acknowledges the receipt of warrants to purchase 1,200,000 shares of Common Stock that have been issued prior to the date of this Note.
| 2 |
Section 2.3 Notice of Corporate Action. If at any time:
(a) the Company shall take a record of the holders of its Common Stock or Series B stock for the purpose of entitling them to receive a dividend or other distribution, or any right to subscribe or purchase any evidences of indebtedness, any shares of stock of any class or any other securities or property, or to receive any other right, or
(b) there shall be any capital reorganization of the Company, any reclassification or recapitalization of the capital stock of the Company or any consolidation or merger of the Company with, or any sale, transfer or other disposition of all or substantially all of the property, assets or business of the Company to, another corporation or,
(c) there shall a voluntary or involuntary dissolution, liquidation or winding up of the Company; then, in any one or more of such cases, the Company shall give to Lender (i) at least 10 days’ prior written notice of the date on which a record date shall be selected for such dividend, distribution or right or for determining rights to vote in respect of any such reorganization, reclassification, merger, consolidation, sale, transfer, disposition, liquidation or winding up, and (ii) in the case of any such reorganization, reclassification, merger, consolidation, sale, transfer, disposition, dissolution, liquidation or winding up, at least 10 days’ prior written notice of the date when the same shall take place. Such notice in accordance with the foregoing clause also shall specify (x) the date on which any such record is to be taken for the purpose of such dividend, distribution or right, the date on which the holders of Common Stock or Series B Stock shall be entitled to any such dividend, distribution or right, and the amount and character thereof, and (y) the date on which any such reorganization, reclassification, merger, consolidation, sale, transfer, disposition, dissolution, liquidation or winding up is to take place and the time, if any such time is to be fixed, as of which the holders of Common Stock or Series B Stock shall be entitled to exchange their shares of Common Stock or series B Stock for securities or other property deliverable upon such disposition, dissolution, liquidation or winding up. Each such written notice shall be sufficiently given if addressed to Lender at the last address of Lender appearing on the books of the Company and delivered in accordance with Section 4.1.
Section 2.4 Restrictions on Securities. This Note has been issued by the Company pursuant to the exemption from registration under the Securities Act of 1933, as amended (the “Act”). None of this Note or the shares of Series B Stock issuable upon conversion of this Note may be offered, sold or otherwise transferred unless (i) they first shall have been registered under the Act and applicable state securities laws or (ii) the Company shall have been furnished with an opinion of legal counsel (in form, substance and scope reasonably acceptable to Company) to the effect that such sale or transfer is exempt from the registration requirements of the Act. Each certificate for shares of Series B Stock issuable upon conversion of this Note that have not been so registered and that have not been sold pursuant to an exemption that permits removal of the applicable legend, shall bear a legend substantially in the following form, as appropriate.
| 3 |
THE SECURITIES REPRESENTED HEREBY HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “ACT”). THE SECURITIES REPRESENTED HEREBY MAY NOT BE OFFERED, SOLD OR OTHERWISE TRANSFERRED UNLESS THEY ARE REGISTERED UNDER THE ACT AND APPLICABLE STATE SECURITIES LAWS, OR SUCH OFFERS, SALES AND TRANSFERS ARE MADE PURSUANT TO AN AVAILABLE EXEMPTION FROM THE REGISTRATION REQUIREMENTS OF THOSE LAWS.
Upon the request of a holder of a certificate representing any shares of Series B Stock issuable upon conversion of this Note, the Company shall remove the foregoing legend from the certificate or issue to such Lender a new certificate free of any transfer legend, if (a) with such request, the Company shall have received an opinion of counsel, reasonably satisfactory to the Company in form, substance and scope, to the effect that any such legend may be removed from such certificate or (b) a registration statement under the Act covering such securities is in effect.
ARTICLE III
MISCELLANEOUS
Section 3.1 Notices. Any notice herein required or permitted to be given shall be in writing and may be personally served or delivered by courier or sent by United States mail and shall be deemed to have been given upon receipt if personally served (which shall include telephone line facsimile transmission) or sent by courier or three (3) days after being deposited in the United States mail, certified, with postage pre-paid and properly addressed, if sent by mail. For the purposes hereof, the address of the Lender shall be 341 Lakewood Drive, Bloomfield Hills, Michigan 48304; and the address of the Company shall be 57 West 57th Street, Suite 400, New York, New York 10019. The Company shall accept electronic notice at “ishimrat@cell-source.com”. Both the Lender and the Company may change the address for service by delivery of written notice to the other as herein provided.
Section 3.2 Entire Agreement and Amendment Provision. This Note represents the entire agreement between the parties hereto with respect to the subject matter hereof and there are no representations, warranties or commitments, except as set forth herein, and replaces and is issued in substitution for the Original Note, which is hereby cancelled. This Note and any provision hereof may be amended only by an instrument in writing signed by the Company and the Lender.
Section 3.3 Assignability. This Note shall be binding upon the Company and its successors and assigns and shall inure to the benefit of the Lender and its successors and assigns; provided, however, that so long as no Event of Default has occurred, this Note shall only be transferable in whole subject to the restrictions contained in the restrictive legend on the first page of this Note.
Section 3.4 Governing Law. This Note shall be governed by the internal laws of the State of New York, without regard to conflicts of laws principles. The parties hereby submit to the exclusive jurisdiction and venue of the state or federal courts sited in the State of New Jersey with respect to any dispute arising under this Note.
| 4 |
Section 3.5 Replacement of Note. The Company covenants that upon receipt by the Company of evidence reasonably satisfactory to it of the loss, theft, destruction or mutilation of this Note, and in case of loss, theft or destruction, of indemnity or security reasonably satisfactory to it (which shall not include the posting of any bond), and upon surrender and cancellation of such Note, if mutilated, the Company will make and deliver a new Note of like tenor.
Section 3.6 This Note shall not entitle the Lender to any of the rights of a stockholder of the Company, including without limitation, the right to vote, to receive dividends and other distributions, or to receive any notice of, or to attend, meetings of stockholders or any other proceedings of the Company, unless and to the extent converted into shares of Series B Stock in accordance with the terms hereof.
Section 3.7 Severability. In case any provision of this Note is held by a court of competent jurisdiction to be excessive in scope or otherwise invalid or unenforceable, such provision shall be adjusted rather than voided, if possible, so that it is enforceable to the maximum extent possible, and the validity and enforceability of the remaining provisions of this Note will not in any way be affected or impaired thereby.
Section 3.8 Headings. The headings of the sections of this Note are inserted for convenience only and do not affect the meaning of such section.
Section 3.9. Replacement. This Note replaces and supersedes the Original Note in its entirety.
Section 3.10 Counterparts. This Note may be executed in multiple counterparts, each of which shall be an original, but all of this shall be deemed to constitute one instrument.
| 5 |
IN WITNESS WHEREOF, with the intent to be legally bound hereby, the Company has executed this Amended and Restated Note on March 2nd, 2021.
| CELL SOURCE, INC. | |||
| By: | /s/ Itamar Shimrat | ||
|
|
| Name: Itamar Shimrat | |
| Title: Chief Executive Officer | |||
|
| LENDER |
| |
|
|
|
|
|
|
|
| /s/ Darlene Soave |
|
|
|
|
| |
| 6 |
Schedule A
Schedule of Loans and Payments
| Date | Amount of Loan | Amount of Principal Paid | Balance Remaining Unpaid | Notation Made By |
| 10-08-2019 | $500,000 |
-0- | $500,000 |
|
| 03-02-2020 | $500,000 | -0- | $500,000 |
|
| 06-019-2021 | $500,000 | -0- | $500,000 |
|
| 12-03-2021 | $500,000 | -0- | $500,000 |
|
| 03-02-2021 | $500,000 | -0- |
$500,000 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| A-I |
EXHIBIT 1
CONVERSION NOTICE
|
|
(To be executed by the Lender in order to Convert the Note)
TO:
The undersigned hereby irrevocably elects to convert US $__________ of the Principal Amount outstanding under the above Note into shares of Series B Convertible Stock of Cell Source, Inc., according to the conditions stated therein. If shares are to be issued in the name of a person other than the undersigned, the undersigned will pay all transfer taxes payable with respect thereto and is delivering herewith such certificates and opinions as reasonably requested by the Company in accordance therewith. No fee will be charged to the Lender for any conversion, except for such transfer taxes, if any.
Conversion Date:_____________________________________________________________________
Applicable Conversion Price: $___________________________________________________________
Signature: ___________________________________________________________
Name: ___________________________________________________________
Address: ___________________________________________________________
___________________________________________________________
Tax I.D. or Soc. Sec. No.: _______________________________________________________________
Principal Amount to be converted: US $____________________________________________________
Amount of Note unconverted: US $_______________________________________________________
Number of shares of Series B Stock to be issued:_____________________________________________
| A-II |
| This ‘10-K’ Filing | Date | Other Filings | ||
|---|---|---|---|---|
 | ||||
| 10/31/21 | ||||
| Filed on: | 4/15/21 | |||
| For Period end: | 12/31/20 | NT 10-K | ||
| 12/3/20 | ||||
| 10/28/19 | ||||
| List all Filings | ||||
As Of Filer Filing For·On·As Docs:Size Issuer Filing Agent 8/08/23 Cell Source, Inc. 10-K 12/31/22 77:11M M2 Compliance LLC/FA 4/15/22 Cell Source, Inc. 10-K 12/31/21 75:11M M2 Compliance LLC/FA |